Laurie B. Keating
2020 - Alnylam Pharmaceuticals
Compensation breakdown
| Non-Equity Incentive Plan | $265,000 |
|---|---|
| Option Awards | $1,598,986 |
| Salary | $544,600 |
| Other | $25,562 |
| Total | $2,434,148 |
Keating received $1.6M in option awards, accounting for 66% of the total pay in 2020.
Keating also received $265K in non-equity incentive plan, $544.6K in salary and $25.6K in other compensation.
Rankings
In 2020, Laurie B. Keating's compensation ranked 4,676th out of 13,090 executives tracked by ExecPay. In other words, Keating earned more than 64.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,676 out of 13,090 | 64th |
Division Manufacturing | 1,901 out of 5,621 | 66th |
Major group Chemicals And Allied Products | 745 out of 2,254 | 67th |
Industry group Drugs | 639 out of 1,954 | 67th |
Industry Pharmaceutical Preparations | 483 out of 1,459 | 67th |
Pay ratio
| Laurie B. Keating's Pay | $2,434,148 |
|---|---|
| Median Employee's Pay | $233,341 |
| Pay Ratio | 10to 1 |
In 2020, the annual total compensation of Laurie B. Keating was $2,434,148.
The annual total compensation of the median employee at Alnylam Pharmaceuticals was $233,341.
The ratio of Laurie B. Keating's pay to the pay of median employee was therefore 10 to one.
Keating's colleagues
We found five more compensation records of executives who worked with Laurie B. Keating at Alnylam Pharmaceuticals in 2020.
2020
Barry Greene
Alnylam Pharmaceuticals
Former President
2020
John Maraganore
Alnylam Pharmaceuticals
Chief Executive Officer
2020
Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Operating Officer
2020
Akshay Vaishnaw
Alnylam Pharmaceuticals
President, Research and Development
2020
Jeffrey Poulton
Alnylam Pharmaceuticals